

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/511,627  
Applicant : Karsten Eulenberg  
Filed : October 18, 2004  
TC/A.U. : 1632  
Examiner : Paul Thomas Dowell

Docket No. : 2923-657  
Customer No. : 6449  
Confirmation No. : 8622

**RESPONSE TO RESTRICTION REQUIREMENT**

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

June 22, 2006

Sir:

In response to the Restriction Requirement dated May 22, 2006, applicants hereby elect group X(ii), claims 25, 27 and 33, with traverse for prosecution in the present application. Applicants also elect CG7956 (synaptojanin-like protein SAC) as the polypeptide. Applicants traverse the restriction requirement on the grounds that group I(viii) should be examined together with group X(ii). Group I(viii) is directed to a pharmaceutical composition comprising a CG7956 polypeptide and thus is the composition used in the claims of group X(ii). Regarding the election of species, applicants elect diabetes as the disorder to start the prior art search.

In the event this paper is not considered to be timely filed, the Applicant respectfully petitions for an appropriate extension of time. Any fee for such an

extension together with any additional fees that may be due with respect to this paper, may be charged to Counsel's Deposit Account No. 02-2135.

Respectfully submitted,

By   
\_\_\_\_\_  
Monica Chin Kitts  
Attorney for Applicants  
Registration No. 36,105  
ROTHWELL, FIGG, ERNST & MANBECK, p.c.  
Suite 800, 1425 K Street, N.W.  
Washington, D.C. 20005  
Telephone: (202)783-6040